This mechanistic data and ongoing research by which EV induces cell death to promote immune cell recruitment and activation provides a potential mechanism underpinning the clinical benefit observed with EV as a monotherapy or in combination with pembrolizumab in mUC.Bernard A. Liu...
Mechanism of Action Enfortumab vedotin is an antibody-drug conjugate (ADC) composed of an anti-nectin-4 monoclonal antibody attached to the cell-killing agent, monomethylauristatin E (MMAE) Nectin-4 is a cell adhesion molecule that is expressed on many solid tumors; once the antibody attaches ...
Based on the mechanism of action and findings in animals, PADCEV can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of enfortumab vedotin-ejfv to pregnant rats during the period of organogenesis caused maternal toxicity, embryo-fetal lethality...
Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and fo...
Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. For more information, see “Selected Important Safety Information” below. “Advanced bladder cancer is a ...
Here, we expand upon the mechanism of action and show EV induces tumor cell killing in a manner leading to immunogenic cell death (ICD) and improves antitumor responses when combined with checkpoint inhibitors. Methods The ability of EV to induce hallmarks of ICD was evaluated in vitro in ...
This was supported based on the mechanism of EV as an ADC against Nectin-4, which has high expression in squamous cell neoplasms [13,14], a documented response in urothelial carcinomas with squamous features [15], and staining on the penectomy specimen (outlined below). The patient was ...
cancers Communication Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma Takashi Kawahara 1,2,* , Akihito Hasizume 1, Koichi Uemura 2, ...